Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial.

Florian Bardet,Cécile Dalban,Christine Chevreau,Sylvie Négrier,Brigitte Laguerre,Gwenaelle Gravis,Marine Gross-Goupil,Stéphane Oudard,Philippe Barthélémy,Jean-Marc Ferrero,Antoine Thiery-Vuillemin,Hakim Mahammedi,Bérangère Narciso,Lionnel Geoffrois,Florence Tantot,Bernard Escudier,Sylvain Ladoire,Laurence Albiges

Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial.

2021

Florian Bardet
Cécile Dalban
Christine Chevreau
Sylvie Négrier
Brigitte Laguerre
Gwenaelle Gravis
Marine Gross-Goupil
Stéphane Oudard
Philippe Barthélémy
Jean-Marc Ferrero
Antoine Thiery-Vuillemin
Hakim Mahammedi
Bérangère Narciso
Lionnel Geoffrois
Florence Tantot
Bernard Escudier
Sylvain Ladoire
Laurence Albiges

e16566Background: Nivolumab monotherapy (N) is a standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies. IMDC criteria is th...

Keywords:

Medicine
Nivolumab
Internal medicine
Oncology
standard of care
Serous fluid
Clear cell renal cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations